BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15533182)

  • 1. Effective HIV treatment and the employment of HIV(+) adults.
    Goldman DP; Bao Y
    Health Serv Res; 2004 Dec; 39(6 Pt 1):1691-712. PubMed ID: 15533182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization.
    Cunningham WE; Markson LE; Andersen RM; Crystal SH; Fleishman JA; Golin C; Gifford A; Liu HH; Nakazono TT; Morton S; Bozzette SA; Shapiro MF; Wenger NS
    J Acquir Immune Defic Syndr; 2000 Oct; 25(2):115-23. PubMed ID: 11103041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between HAART use and employment for HIV-positive individuals: an empirical analysis and policy outlook.
    Bernell SL; Shinogle JA
    Health Policy; 2005 Feb; 71(2):255-64. PubMed ID: 15607387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Joint longitudinal data analysis in detecting determinants of CD4 cell count change and adherence to highly active antiretroviral therapy at Felege Hiwot Teaching and Specialized Hospital, North-west Ethiopia (Amhara Region).
    Seyoum A; Ndlovu P; Temesgen Z
    AIDS Res Ther; 2017 Mar; 14(1):14. PubMed ID: 28302125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience.
    Erhabor O; Ejele OA; Nwauche CA
    Niger J Clin Pract; 2006 Dec; 9(2):128-33. PubMed ID: 17319344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.
    Djomand G; Roels T; Ellerbrock T; Hanson D; Diomande F; Monga B; Maurice C; Nkengasong J; Konan-Koko R; Kadio A; Wiktor S; Lackritz E; Saba J; Chorba T
    AIDS; 2003 Jul; 17 Suppl 3():S5-15. PubMed ID: 14565604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insurance status of HIV-infected adults in the post-HAART era: evidence from the United States.
    Goldman DP; Leibowitz AA; Joyce GF; Fleishman JA; Bozzette SA; Duan N; Shapiro MF
    Appl Health Econ Health Policy; 2003; 2(2):85-90. PubMed ID: 14619279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study.
    Patroni A; Torti C; Tomasoni L; Quiros Roldan E; Bertelli D; Puoti M; Cadeo GP; Sleiman I; Tinelli C; Carosi G; Castelli F
    HIV Clin Trials; 2002; 3(6):451-61. PubMed ID: 12501128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inability to take medications openly at home: does it help explain gender disparities in HAART use?
    Sayles JN; Wong MD; Cunningham WE
    J Womens Health (Larchmt); 2006 Mar; 15(2):173-81. PubMed ID: 16536681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
    Brogan A; Mauskopf J; Talbird SE; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
    Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
    Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting first month adherence due to antiretroviral therapy among HIV-positive adults at Felege Hiwot Teaching and Specialized Hospital, north-western Ethiopia; a prospective study.
    Tegegne AS; Ndlovu P; Zewotir T
    BMC Infect Dis; 2018 Feb; 18(1):83. PubMed ID: 29458343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV antiretroviral treatment: early versus later.
    Mauskopf J; Kitahata M; Kauf T; Richter A; Tolson J
    J Acquir Immune Defic Syndr; 2005 Aug; 39(5):562-9. PubMed ID: 16044008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive effects of body mass index on immune reconstitution among HIV-infected HAART users in China.
    Li X; Ding H; Geng W; Liu J; Jiang Y; Xu J; Zhang Z; Shang H
    BMC Infect Dis; 2019 May; 19(1):373. PubMed ID: 31046702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
    Sterling TR; Chaisson RE; Moore RD
    AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.